Miami Cancer Institute to Present Latest Neuro-Oncology Research at 2023 SNO Annual Meeting
MIAMI & TAMPA, FL – November 10, 2023 – Miami Cancer Institute, part of Baptist Health South Florida, announced it will give two oral and eight poster presentations at this year’s annual meeting of the Society for Neuro-Oncology (SNO), November 15-19, at the Vancouver Convention Centre in Vancouver, British Columbia, Canada. The presentations will cover the latest developments in the treatment of glioblastoma and brain metastases, liquid biopsies, and brain-barrier disruption, among many others. Miami Cancer Institute will also participate in a workshop on neuro-oncology clinical trials and speak at a lunch session on SNO guidelines.
“Our presentations at SNO this year represent the latest developments in many exciting areas of research in neuro-oncology,” said Manmeet Singh Ahluwalia, M.D., MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of Miami Cancer Institute, and Fernandez Family Foundation Endowed Chair in Cancer Research. “My colleagues and I will present findings in the treatment of glioblastoma – one of the hardest to treat forms of brain cancer – as well as new therapeutic approaches for several forms of brain metastases, among others.”
Miami Cancer Institute’s presentations at SNO 2023 include:
Oral Presentations
Friday, November 17, 2023
CTNI-21 - Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): final trial report
Presenter: Manmeet S. Ahluwalia, M.D., MBA,FASCO
Time: 5:05 – 5:10 p.m. PT
Location: Room 109-110
Saturday, November 18, 2023
RANO-RT
Presenter: Minesh P. Mehta, M.D.
Time: 4:49 – 4:57 p.m. PT
Location: Exhibit Hall C
Poster Presentations
Friday, November 17, 2023
CTNI-08 - Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): a multicenter phase 1 clinical trial
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 7:30 – 9:30 p.m. PT
Location: Exhibit Hall A/B
CTNI-55 - A multicenter study of low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE)
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 7:30 – 9:30 p.m. PT
Location: Exhibit Hall A/B
DNAR-05 - Exceptional Responders to Base Excision Repair (BER) Inhibition for Recurrent Glioblastoma Display Enrichment for DNA Damage Response Pathways: RNA Sequencing Analysis from a Multicenter Trial
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 7:30 – 9:30 p.m. PT
Location: Exhibit Hall A/B
IMMU-34 - Systemic immune suppression in glioblastoma is targeted by concurrent VEGF and PD-1 inhibition in a dose-dependent manner: transcriptomic findings through CITE-Seq from a randomized controlled trial
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 7:30 – 9:30 p.m. PT
Location: Exhibit Hall A/B
PATH-01 - Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease
Presenter: Yazmin Odia, M.D.
Time: 7:30 – 9:30 p.m. PT
Location: Exhibit Hall A/B
RTID-01 - A randomized study of low-intensity focused ultrasound for blood-brain barrier disruption for brain metastasis from non-small cell lung cancer (LIMITLESS)
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 7:30 – 9:30 p.m. PT
Location: Exhibit Hall A/B
RTID-06 - The pivotal METIS (EF-25) study of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) following radiosurgery
Presenter: Minesh P Mehta, M.D.
Time: 7:30 – 9:30 p.m. PT
Location: Exhibit Hall A/B
SURG-27 - 17-year experience of surgical management of intradural extramedullary (IDEM) tumors: clinical outcomes from a low- and middle-income country
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 7:30 – 9:30 p.m. PT
Location: Exhibit Hall A/B
Workshop
Wednesday, November 15, 2023
Clinical Trial Design Workshop: Panel 1 -- Pearls and Pitfalls in Conducting Neuro-Oncology Clinical Trials: Reflections of Experienced Clinical Trialists
Panelist: Minesh P. Mehta, M.D.
Time: 10:30 – 11:30 a.m. PT
Location: Ballroom B
Lunch Session
Friday, November 17, 2023
SNO Guidelines: Everything You Wanted to Know But Were Afraid to Ask
Speaker: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 12:45 – 1:45 p.m. PT
Location: Room 301
For updates from the 2023 SNO Annual Meeting, look for #SNO2023 on social media and follow Miami Cancer Institute on Twitter at @MiamiCancerInst.
About Miami Cancer Institute
Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK. For more information, please visit https://baptisthealth.net/services/cancer-care/miami-cancer-institute.
Miami Cancer Institute is part of Baptist Health Cancer Care, the largest cancer program in South Florida, with locations from the Florida Keys to the Palm Beaches.
###
